Midkiff K, Harris D, Gilsenan A, Andrews E. Studying cancer as an adverse outcome from nononcological therapies: review of the Food and Drug Administration's postmarketing commitment database. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.
Midkiff KD, Andrews EB, Gilsenan AW, Harris DH. "First in Flight" or "When Pigs Fly" – Can cancer registries play a critical role at the national level in studying cancer as an adverse outcome from drug treatments? Presented at the NAACCR 2015 Annual Conference; June 2015. Charlotte, NC.
Midkiff KD, Gilsenan AW, Andrews EB, Masica D, Ceberg J, Alvegard T. Findings from the postmarketing adult osteosarcoma surveillance study in the Nordic countries. Poster presented at the 37th Meeting of the Scandinavian Sarcoma Group; May 20, 2015. Stockholm, Sweden.
Andrews EB, Gilsenan AW, Midkiff KD, Harris DH. Comments on Bang et al.: the impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2015 May;26(5):1663-4. doi: 10.1007/s00198-014-3003-z